Group: sci.med.diseases.cancer
Diagnosis, treatment, and prevention of cancer.
Add group to favorites
Back to post list
Send new message to group Search:
Post Subject:
Chemical Compound Prevents Cancer In Lab
Chemical Compound Prevents Cancer In Lab
http :// www .ouhsc.edu/article-display.asp?idnum35
Announcement
April 25, 2008
Chemical Compound Prevents Cancer In Lab
Researchers study several compounds to stop or prevent cancer
OU Public Affairs
Oklahoma City, OK -- While researching new ways to stop the progression of
cancer, researchers at the University of Oklahoma Health Sciences Center,
have discovered a compound that has shown to prevent cancer in the
laboratory.
The compound, which still faces several rounds of clinical trials,
successfully stopped normal cells from turning into cancer cells and
inhibited the ability of tumors to grow and form blood vessels. If
successful tests continue, researchers eventually hope to create a daily
pill that would be taken as a cancer preventive.
"This compound was effective against the 12 types of cancers that it was
tested on," said Doris Benbrook, Ph.D., principle investigator and
researcher at the OU Cancer Institute. "Even more promising for health care
is that it prevents the transformation of normal cells into cancer cells and
is therefore now being developed by the National Cancer Institute as a
cancer prevention drug."
The synthetic compound, SHetA2, a Flex-Het drug, directly targets
abnormalities in cancer cell components without damaging normal cells. The
disruption causes cancer cells to die and keeps tumors from forming.
Flex-Hets or flexible heteroarotinoids are synthetic compounds that can
change certain parts of a cell and affect its growth. Among the diseases and
conditions being studied for treatment with Flex-Hets are polycystic kidney
disease, kidney cancer and ovarian cancer.
Benbrook and her research team have patented the Flex-Het discovery and hope
to start clinical trials for the compound within 5 years. If the compound is
found to be safe, it would be developed into a pill to be taken daily like a
multi-vitamin to prevent cancer.
The compound also could be used to prevent cancer from returning after
traditional radiation and chemotherapy treatments, especially in cancers
that are caught in later stages such as ovarian cancer where life expectancy
can be as short as 6 months after treatment.
"It would be a significant advancement in health care if this pill is
effective in preventing cancer, and we could avoid the severe toxicity and
suffering that late stage cancer patients have to experience," Benbrook
said.
--
Gruß Guybrush
http :// www .ouhsc.edu/article-display.asp?idnum35
Announcement
April 25, 2008
Chemical Compound Prevents Cancer In Lab
Researchers study several compounds to stop or prevent cancer
OU Public Affairs
Oklahoma City, OK -- While researching new ways to stop the progression of
cancer, researchers at the University of Oklahoma Health Sciences Center,
have discovered a compound that has shown to prevent cancer in the
laboratory.
The compound, which still faces several rounds of clinical trials,
successfully stopped normal cells from turning into cancer cells and
inhibited the ability of tumors to grow and form blood vessels. If
successful tests continue, researchers eventually hope to create a daily
pill that would be taken as a cancer preventive.
"This compound was effective against the 12 types of cancers that it was
tested on," said Doris Benbrook, Ph.D., principle investigator and
researcher at the OU Cancer Institute. "Even more promising for health care
is that it prevents the transformation of normal cells into cancer cells and
is therefore now being developed by the National Cancer Institute as a
cancer prevention drug."
The synthetic compound, SHetA2, a Flex-Het drug, directly targets
abnormalities in cancer cell components without damaging normal cells. The
disruption causes cancer cells to die and keeps tumors from forming.
Flex-Hets or flexible heteroarotinoids are synthetic compounds that can
change certain parts of a cell and affect its growth. Among the diseases and
conditions being studied for treatment with Flex-Hets are polycystic kidney
disease, kidney cancer and ovarian cancer.
Benbrook and her research team have patented the Flex-Het discovery and hope
to start clinical trials for the compound within 5 years. If the compound is
found to be safe, it would be developed into a pill to be taken daily like a
multi-vitamin to prevent cancer.
The compound also could be used to prevent cancer from returning after
traditional radiation and chemotherapy treatments, especially in cancers
that are caught in later stages such as ovarian cancer where life expectancy
can be as short as 6 months after treatment.
"It would be a significant advancement in health care if this pill is
effective in preventing cancer, and we could avoid the severe toxicity and
suffering that late stage cancer patients have to experience," Benbrook
said.
--
Gruß Guybrush
